Deletion of AMP-activated protein kinase impairs metastasis and is rescued by ROS scavenging or ectopic CD36 expression.

Cell Rep

Department of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago, Chicago, IL 60607, USA; Research and Development Section, Jesse Brown VA Medical Center, Chicago, IL 60612, USA. Electronic address:

Published: January 2025

AMPK's role in tumor initiation and progression is controversial. Here, we provide genetic evidence that AMPK is required for metastasis in mouse models of breast cancer. In a mouse model of spontaneous breast cancer metastasis, the deletion of AMPK before and after tumor onset decreased breast cancer metastasis, and similar results were obtained after AMPK deletion in breast cancer cell lines. The deletion of AMPK induces reactive oxygen species (ROS) levels in vitro and lipid oxidation in vivo, which likely impede metastasis. Indeed, antioxidants restore the ability of AMPK-deficient tumors to metastasize. By inhibiting acetyl-coenzyme A (CoA) carboxylases 1 and 2, AMPK maintains NADPH levels by reducing NADPH consumption in fatty acid synthesis and increasing NADPH generation via fatty acid oxidation, thus increasing the dependency on auxotrophic fatty acids. Consistently, AMPK is required for the expression of the fatty acid transporter CD36 in tumors, and ectopic expression of CD36 in AMPK-deficient cells restored their ability to metastasize.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2024.115183DOI Listing

Publication Analysis

Top Keywords

breast cancer
16
fatty acid
12
ampk required
8
cancer metastasis
8
deletion ampk
8
ampk
6
metastasis
5
deletion
4
deletion amp-activated
4
amp-activated protein
4

Similar Publications

Tumor heterogeneity remains a formidable obstacle in targeted cancer therapy, often leading to suboptimal treatment outcomes. This study presents an innovative approach that harnesses controlled inflammation to guide neutrophil-mediated drug delivery, effectively overcoming the limitations imposed by tumor heterogeneity. By inducing localized inflammation within tumors using lipopolysaccharide, it significantly amplify the recruitment of drug-laden neutrophils to tumor sites, irrespective of specific tumor markers.

View Article and Find Full Text PDF

Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how changes in the Ki67 biomarker before and after neoadjuvant chemotherapy (NACT) affect survival in patients with triple-negative breast cancer (TNBC).
  • Among 1,777 TNBC patients analyzed, most showed a decrease in tumor size and Ki67 levels after NACT, though many had no change or experienced treatment discontinuation.
  • Patients with unchanged Ki67 had significantly worse overall and disease-specific survival compared to those with decreased Ki67, emphasizing the need for personalized treatment strategies based on ongoing monitoring of this biomarker.
View Article and Find Full Text PDF

Elevated MRPS23 expression facilitates aggressive phenotypes in breast cancer cells.

Cell Mol Biol (Noisy-le-grand)

January 2025

Department of Integrative Medicine, Huashan Hospital, Fudan University, Shanghai, China.

Mitochondrial ribosomal protein S23 (MRPS23), encoded by a nuclear gene, is a well-known driver of proliferation in cancer. It participates in mitochondrial protein translation, and its expression association has been explored in many types of cancer. However, MRPS23 expression associations are rarely reported in breast cancer (BC).

View Article and Find Full Text PDF

In this study, the effects of histone deacetylase inhibitor CI-994 and nanotechnological drug liposomal cisplatin LipoPlatin on Luminal A breast cancer and triple-negative breast cancer were explored using agents alone and in combination. MCF-7 and MDA-MB-231 cell lines were used. Cell viability, and cell index values obtained from xCELLigence System, MI, BrdU LI and AI were evaluated in experiments.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!